Rifabutin-based Triple Therapy After Failure of Helicobacter pylori Eradication Treatment
- 1 October 2000
- journal article
- research article
- Published by Wolters Kluwer Health in Journal of Clinical Gastroenterology
- Vol. 31 (3), 222-225
- https://doi.org/10.1097/00004836-200010000-00007
Abstract
Despite continuous improvement of Helicobacter pylori (Hp) eradication therapy, new treatment regimens are necessary if established first-line treatments fail. In the present pilot study, a recently described rifabutin-based triple therapy was evaluated after preceding failure of triple therapy. Rifabutin (150 mg), amoxicillin (1 g), and lansoprazole (30 mg) were administered twice daily for 1 week to 25 patients infected with Hp who had previously failed to respond to eradication treatment and/or who had developed resistance to macrolides and nitroimidazoles. Four patients were lost to follow-up. Eradication rate of rifabutin-based triple therapy was 86% (18/21; per-protocol) and 72% (18/25; intention-to-treat). Side effects were minimal. It is concluded that this new drug combination is an effective therapy for Hp strains resistant to clarithromycin or metronidazole; however, rifabutin-based treatment regimens for Hp eradication should be restricted to patients infected with resistant strains.Keywords
This publication has 13 references indexed in Scilit:
- The importance of clarithromycin dose in the management of Helicobacter pylori infection: a meta‐analysis of triple therapies with a proton pump inhibitor, clarithromycin and amoxycillin or metronidazoleAlimentary Pharmacology & Therapeutics, 1999
- The GU‐MACH study: the effect of 1‐week omeprazole triple therapy on Helicobacter pylori infection in patients with gastric ulcerAlimentary Pharmacology & Therapeutics, 1999
- In Vitro Anti- Helicobacter pylori Activities of New Rifamycin Derivatives, KRM-1648 and KRM-1657Antimicrobial Agents and Chemotherapy, 1999
- The effect of antibiotic resistance on the outcome of three 1‐week triple therapies against Helicobacter pyloriAlimentary Pharmacology & Therapeutics, 1999
- Treatment options for Helicobacter pylori infection when proton pump inhibitor‐based triple therapy fails in clinical practiceAlimentary Pharmacology & Therapeutics, 1999
- The MACH2 study: Role of omeprazole in eradication of Helicobacter pylori with 1-week triple therapiesGastroenterology, 1999
- One‐week clarithromycin triple therapy regimens for eradication of Helicobacter pyloriAlimentary Pharmacology & Therapeutics, 1998
- Treatment of Antibiotic-ResistantHelicobacter pyloriInfectionNew England Journal of Medicine, 1998
- Current European concepts in the management of Helicobacter pylori infection. The Maastricht Consensus Report. European Helicobacter Pylori Study Group.Gut, 1997
- Eradication of Helicobacter pylori Using One‐week Triple Therapies Combining Omeprazole with Two Antimicrobials: The MACH I StudyHelicobacter, 1996